FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566366231> ?p ?o ?g. }

• W1566366231 abstract "OBJECTIVE: To determine the prevalence of anti-JC virus (JCV) antibodies in multiple sclerosis (MS) patients from Canada. BACKGROUND: Seroprevalence of anti-JCV antibodies in the general population has been reported over a wide range from 39-91%, depending on assay methodology and population studied. DESIGN/METHODS: This cross-sectional, multicenter epidemiology study consisted of one visit at which patient information (birthdate, gender, race, type and duration of MS, and number and duration of MS therapies) and one blood sample were collected for analysis of anti-JCV antibodies using a two-step enzyme-linked immunosorbent assay (ELISA; STRATIFY JCV TM ). Chi-square and logistic regression (univariate and multivariate) analyses were used to evaluate anti-JCV antibody prevalence by demographics, geographic region, disease characteristics and treatment. RESULTS: The study included 4198 Canadian MS patients. Overall anti-JCV antibody prevalence was 56.3% (95% confidence interval [CI]: 54.8-57.8). Seroprevalence was significantly associated with increasing age and male gender ( P P =0.0051). Anti-JCV antibody prevalence was not associated with race, MS disease subtype and disease duration, or number and duration of treatments. MS patients with prior use of immunosuppressive therapy had a higher seroprevalence rate (63.4%; 95% CI: 56.6-69.9) compared with those who had not received immunosuppressive therapy (55.9%; 95% CI: 54.4-57.5; P =0.04, adjusted for age, gender, and region). CONCLUSIONS: The overall estimated anti-JCV antibody prevalence rate in Canada was 56.3%. This finding is consistent with previous experience with the assay, which detected positivity in 55% of natalizumab-treated MS patients ( Ann Neurol 2010;68:295-303). We found significant associations of anti-JCV antibody positivity with region, age, gender and prior immunosuppressive therapy, whereas seroprevalence was not associated with race, MS type, duration of MS or number or duration of MS treatments. Study Supported by: Biogen Idec. Disclosure: Dr. Bhan has received personal compensation for activities with Biogen Idec, Serono Inc., Genzyme Corporation, Novartis and Teva Neuroscience. Dr. Lapierre has received personal compensation for activities with Serono, Inc. and Novartis as a scientific advisory board member and speaker, and with Biogen Idec as a speaker. Dr. Lapierre has received personal compensation in an editorial capacity for Teva Neuroscience. Dr. Freedman has received personal compensation for activities with Bayer Pharmaceuticals Inc., Genzyme Corp., EMD Canada, Novartis, Sanofi-Aventis Pharmaceuticals, Inc., Celgene, Glycominds, and Teva Neuroscience. Dr. Duquette has received personal compensation for activities with Berlex, Biogen Idec, Serono, Novartis, and Teva Neuroscience. Dr. Selchen has received personal compensation for activities with Teva Neuroscience, Merck Serono, Genzyme Corp., Novartis, Biogen Idec, Bristol-Myers Squibb Co. and Boerhinger Ingelheim Pharmaceuticals Inc. Dr. Migounov has received personal compensation for activities with Biogen Idec. Dr. Walt has received personal compensation for activities with Biogen Idec as an employee. Dr. Zhang has received personal compensation for activities with Biogen Idec." @default.
• W1566366231 created "2016-06-24" @default.
• W1566366231 creator A5018362195 @default.
• W1566366231 creator A5021092653 @default.
• W1566366231 creator A5023547051 @default.
• W1566366231 creator A5029937467 @default.
• W1566366231 creator A5031140141 @default.
• W1566366231 creator A5049397227 @default.
• W1566366231 creator A5050442625 @default.
• W1566366231 creator A5051605203 @default.
• W1566366231 date "2014-04-08" @default.
• W1566366231 modified "2023-09-22" @default.
• W1566366231 title "Anti-JC Virus Antibody Prevalence in Canadian MS Patients (P4.141)" @default.
• W1566366231 hasPublicationYear "2014" @default.
• W1566366231 type Work @default.
• W1566366231 sameAs 1566366231 @default.
• W1566366231 citedByCount "0" @default.
• W1566366231 crossrefType "journal-article" @default.
• W1566366231 hasAuthorship W1566366231A5018362195 @default.
• W1566366231 hasAuthorship W1566366231A5021092653 @default.
• W1566366231 hasAuthorship W1566366231A5023547051 @default.
• W1566366231 hasAuthorship W1566366231A5029937467 @default.
• W1566366231 hasAuthorship W1566366231A5031140141 @default.
• W1566366231 hasAuthorship W1566366231A5049397227 @default.
• W1566366231 hasAuthorship W1566366231A5050442625 @default.
• W1566366231 hasAuthorship W1566366231A5051605203 @default.
• W1566366231 hasConcept C107130276 @default.
• W1566366231 hasConcept C126322002 @default.
• W1566366231 hasConcept C151956035 @default.
• W1566366231 hasConcept C159654299 @default.
• W1566366231 hasConcept C203014093 @default.
• W1566366231 hasConcept C2778494684 @default.
• W1566366231 hasConcept C2779150272 @default.
• W1566366231 hasConcept C2780640218 @default.
• W1566366231 hasConcept C2780644213 @default.
• W1566366231 hasConcept C2908647359 @default.
• W1566366231 hasConcept C44249647 @default.
• W1566366231 hasConcept C45189115 @default.
• W1566366231 hasConcept C71924100 @default.
• W1566366231 hasConcept C99454951 @default.
• W1566366231 hasConceptScore W1566366231C107130276 @default.
• W1566366231 hasConceptScore W1566366231C126322002 @default.
• W1566366231 hasConceptScore W1566366231C151956035 @default.
• W1566366231 hasConceptScore W1566366231C159654299 @default.
• W1566366231 hasConceptScore W1566366231C203014093 @default.
• W1566366231 hasConceptScore W1566366231C2778494684 @default.
• W1566366231 hasConceptScore W1566366231C2779150272 @default.
• W1566366231 hasConceptScore W1566366231C2780640218 @default.
• W1566366231 hasConceptScore W1566366231C2780644213 @default.
• W1566366231 hasConceptScore W1566366231C2908647359 @default.
• W1566366231 hasConceptScore W1566366231C44249647 @default.
• W1566366231 hasConceptScore W1566366231C45189115 @default.
• W1566366231 hasConceptScore W1566366231C71924100 @default.
• W1566366231 hasConceptScore W1566366231C99454951 @default.
• W1566366231 hasLocation W15663662311 @default.
• W1566366231 hasOpenAccess W1566366231 @default.
• W1566366231 hasPrimaryLocation W15663662311 @default.
• W1566366231 hasRelatedWork W1992821990 @default.
• W1566366231 hasRelatedWork W2115639141 @default.
• W1566366231 hasRelatedWork W2130776183 @default.
• W1566366231 hasRelatedWork W2181725647 @default.
• W1566366231 hasRelatedWork W2258778881 @default.
• W1566366231 hasRelatedWork W2327880443 @default.
• W1566366231 hasRelatedWork W2784416211 @default.
• W1566366231 hasRelatedWork W2968865792 @default.
• W1566366231 hasVolume "82" @default.
• W1566366231 isParatext "false" @default.
• W1566366231 isRetracted "false" @default.
• W1566366231 magId "1566366231" @default.
• W1566366231 workType "article" @default.